Hypoxia-inducible factor alpha (HIF-α) (HIF-α)

Hypoxia-inducible factor alpha (HIF-α) is a critical transcription factor that serves as the primary regulator of the mammalian response to low oxygen environments. It exists in three isoforms—HIF-1α, HIF-2α, and HIF-3α—which dimerize with the constitutively expressed HIF-1β subunit to modulate the expression of genes involved in erythropoiesis, vascularization, and anaerobic metabolism (UniProt, 2024). In healthy cells, HIF-α is continuously synthesized but rapidly degraded in the presence of oxygen through a process involving prolyl hydroxylase (PHD) enzymes and the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex (StatPearls, 2023). Pathologically, over-stabilization of HIF-α is a hallmark of various cancers, particularly clear cell renal cell carcinoma, where it drives tumor growth and angiogenesis. Therapeutic strategies include HIF-2α inhibitors like belzutifan for oncology and HIF prolyl hydroxylase inhibitors (HIF-PHIs) like roxadustat, which stabilize HIF-α to treat anemia associated with chronic kidney disease (FDA, 2021; Nature Reviews Drug Discovery, 2022).

Other names

HIF-1-alphaHIF-2-alphaHIF-3-alphaHIF1AEPAS1HIF3AEndothelial PAS domain-containing protein 1Member of PAS protein 1 (MOP1)PAS domain-containing protein 8

Direct antagonism of the HIF-2α PAS-B domain to prevent heterodimerization with HIF-1β; Indirect stabilization of HIF-α subunits through the inhibition of prolyl hydroxylase domain (PHD) enzymes, which prevents oxygen-dependent degradation (Nature Reviews Drug Discovery, 2022; FDA, 2021).